文献速递细菌感染、耐药与抗菌药物医院感染防控

达巴万星对感染性心内膜炎患者分离革兰阳性菌的体外抗菌活性

Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

该研究通过SENTRY监测项目收集2007至2017年美国(n=222)和欧洲(n=404)感染性心内膜炎患者共626株革兰阳性菌,用微量肉汤稀释法检测达巴万星及对照药物敏感性。达巴万星对金黄色葡萄球菌、粪肠球菌、草绿链球菌群和凝固酶阴性葡萄球菌均显示强效体外活性,支持进一步研究其在感染性心内膜炎治疗中的作用。

要点

  • 达巴万星对心内膜炎患者分离的金黄色葡萄球菌和粪肠球菌敏感率分别为100.0%和97.6%。
  • 达巴万星对金黄色葡萄球菌的MIC值较达托霉素低4至8倍。

核心结论

  • 达巴万星对美国和欧洲感染性心内膜炎患者分离的大量革兰阳性菌显示强效体外活性。
  • 结果支持进一步研究达巴万星在感染性心内膜炎治疗中的作用。

研究设计与样本

  • 通过SENTRY抗菌药物监测项目收集2007至2017年美国(n=222)和欧洲(n=404)感染性心内膜炎患者共626株革兰阳性菌。
  • 采用微量肉汤稀释法检测达巴万星及对照药物对分离菌的敏感性。

主要发现

  • 最常见病原体为金黄色葡萄球菌(48.4%)、粪肠球菌(19.6%)和草绿链球菌群(12.5%)。
  • 达巴万星和达托霉素对金黄色葡萄球菌按CLSI标准敏感率均为100.0%,但达巴万星MIC值低4至8倍。
  • 粪肠球菌对达巴万星敏感率为97.6%(MIC90 0.06 mg/L),对万古霉素敏感率为96.7%(MIC90 2 mg/L)。
  • 所有草绿链球菌群和凝固酶阴性葡萄球菌对达巴万星、达托霉素、万古霉素和利奈唑胺均敏感。
  • 屎肠球菌中65.7%被≤0.25 mg/L达巴万星抑制,62.9%对万古霉素敏感。

关键数值与推荐

  • 达巴万星对金黄色葡萄球菌按CLSI标准敏感率100.0%。
  • 达巴万星对粪肠球菌敏感率97.6%,MIC90为0.06 mg/L;万古霉素对粪肠球菌敏感率96.7%,MIC90为2 mg/L。
  • 头孢洛林对所有MSSA(MIC90 0.25 mg/L)及78.4%的MRSA在≤1 mg/L时具有活性。
  • 屎肠球菌中65.7%被≤0.25 mg/L达巴万星抑制,62.9%对万古霉素敏感。

临床怎么用

  • 达巴万星对心内膜炎常见革兰阳性菌具有强效体外活性,可考虑作为潜在治疗选择。
  • 目前数据为体外药敏结果,尚需临床研究确定达巴万星在感染性心内膜炎治疗中的角色。

局限性

  • 研究仅评估体外抗菌活性,未提供临床疗效或安全性数据。
  • 菌株来源于监测项目,可能存在选择偏倚。
  • 屎肠球菌对达巴万星和万古霉素的敏感率较低,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The management of endocarditis requires aggressive and prolonged antimicrobial treatment. We evaluated the in vitro activity of dalbavancin against bacteria from patients with infective endocarditis. METHODS: A total of 626 Gram-positive organisms were collected from patients with a diagnosis of bacterial endocarditis in the USA (n = 222) and Europe (n = 404) from 2007 to 2017 via the SENTRY Antimicrobial Surveillance Program and were tested for susceptibility to dalbavancin and comparators by broth microdilution. RESULTS: The most common organisms were Staphylococcus aureus (48.4%), Enterococcus faecalis (19.6%) and viridans group streptococci (VGS; 12.5%). Dalbavancin and daptomycin showed complete activity (100.0% susceptibility per CLSI criteria) against S. aureus, but dalbavancin MIC values were 4- to 8-fold lower. Vancomycin, linezolid and teicoplanin were also active against all S. aureus when CLSI criteria were applied. Ceftaroline was active against all MSSA (MIC90 0.25 mg/L) and 78.4% of MRSA isolates at ≤1 mg/L. All E. faecalis isolates were susceptible to ampicillin, daptomycin and linezolid, whereas 97.6% of isolates were susceptible to dalbavancin (MIC90 0.06 mg/L) and 96.7% were susceptible to vancomycin (MIC90 2 mg/L). All VGS and CoNS isolates were susceptible to dalbavancin, daptomycin, vancomycin and linezolid. Against Enterococcus faecium, 65.7% of isolates were inhibited by ≤0.25 mg/L dalbavancin and 62.9% were vancomycin susceptible. CONCLUSIONS: Dalbavancin exhibited potent in vitro activity against a large collection of Gram-positive isolates recovered from patients with endocarditis in US and European medical centres. These results support further investigations to determine the role of dalbavancin in the treatment of infective endocarditis.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Sader HS, Mendes RE, Pfaller MA, et al. Antimicrobial activity of dalbavancin tested against Gram-positive organisms isolated from patients with infective endocarditis in US and European medical centres. J Antimicrob Chemother. 2019. PMID: 30753485. doi:10.1093/jac/dkz006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。